exRNAdisease

Entry Detail

---



General Information

Database ID: exR0275953 RNA Name: hsa-miR-92a-3p RNA Type: miRNA Chromosome: chrX Starnd: - Coordinate: Start Site(bp): 134169544 End Site(bp): 134169565 External Links: hsa-miR-92a-3p

Disease Information

Disease Name: Advanced Adenoma Disease Category: Cancers MeSH ID: D000236 Type: Neoplasms/Neoplasms, Glandular and Epithelial Alias: Adenoma//Adenomas//Adenoma, Follicular//Adenomas, Follicular//Follicular Adenoma//Follicular Adenomas//Adenoma, Trabecular//Adenomas, Trabecular//Trabecular Adenoma//Trabecular Adenomas//Adenoma, Monomorphic//Adenomas, Monomorphic//Monomorphic Adenoma//Monomorphic Adenomas//Adenoma, Papillary//Adenomas, Papillary//Papillary Adenoma//Papillary Adenomas//Adenoma, Basal Cell//Adenomas, Basal Cell//Basal Cell Adenoma//Basal Cell Adenomas//Adenoma, Microcystic//Adenomas, Microcystic//Microcystic Adenoma//Microcystic Adenomas

Expression Detail

GEO ID: GSE25609 Description: Plasma microRNA profiling by microarray elucidates several candidate biomarkers for colorectal cancer screening Experimental Design: Cancer vs Control Case Disease Type: Advanced Adenoma Case Disease SubType: NA Case Sample: Advanced Adenoma Post surgery Control Sample: Control Number of Case: 20 Number of Control: 20 Number of Samples: 40

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand MAZ chr16 29806106 29811164 + RPS8 chr1 44775251 44778779 + ESRP1 chr8 94641074 94707466 + PTPRZ1 chr7 121873089 122062036 + YIPF3 chr6 43511832 43516985 - SEC63 chr6 107867756 107958208 - NPM1 chr5 171387116 171411137 + USP21 chr1 161159450 161165723 + ZNF330 chr4 141220887 141234697 + HBE1 chr11 5268345 5505652 - EHMT2 chr6 31879759 31897687 - PITPNA chr17 1517718 1562792 - RBBP5 chr1 205086142 205122015 - PNKD chr2 218270392 218346793 + SMC1A chrX 53374149 53422728 - RWDD1 chr6 116571409 116597675 + GLCE chr15 69160584 69272217 + CEP89 chr19 32875925 32971991 - PPP3CB chr10 73436428 73496024 - HMGB1 chr13 30456704 30617597 - KLF4 chr9 107484852 107490482 - MRPS16 chr10 73248843 73252693 - TCP1 chr6 159778498 159789703 - EZR chr6 158765741 158819368 - PSMB8 chr6 32840717 32844679 - RPL17-C18orf32 chr18 49481681 49492479 - OGFOD1 chr16 56451521 56479104 + MCM3 chr6 52264014 52284881 - EIF4G2 chr11 10797050 10808940 - RPL13A chr19 49487554 49492308 + miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0001005 chr2 53921020 53978078 - hsa_circ_0001414 chr4 56277780 56284152 + hsa_circ_0000126 chr1 150997086 150999803 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC005394.2 chr19 28435388 28727680 - AC074117.1 chr2 27356246 27367622 + AC130650.2 chr16 14150833 14153235 + DAPK1-IT1 chr9 87553454 87554459 + LINC01128 chr1 825138 859446 + MALAT1 chr11 65497688 65506516 + NORAD chr20 36045618 36051018 - OIP5-AS1 chr15 41283990 41309737 + PITPNA-AS1 chr17 1516931 1518096 + PURPL chr5 27217714 27496994 + SNHG5 chr6 85650491 85678932 - XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE25609 Sample Source: Blood Source Fraction: Plasma Platform: GPL8179 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 826 Sample treatment protocol: Briefly, samples were centrifuged at 1,600×g for 10 min at 4 ºC to spin down blood cells, and plasma was transferred into new tubes, followed by further centrifugation at 16,000×g for 10 minutes at 4ºC to completely remove cellular components. RNA Extract protocol: NA RNA library preparation protocol: Biotinylated cDNA were prepared with the Illumina® TotalPrep™ RNA Amplification Kit (Ambion).

Reference

PMID: 23267864 Title: Circulating microRNAs as biomarkers of colorectal cancer: results from a genome-wide profiling and validation study Author: Gir¨¢ldez MD, Lozano JJ, Ram¨ªrez G, Hijona E, Bujanda L, Castells A, Gironella M Journal: Clin Gastroenterol Hepatol. 2013 Jun;11(6):681-8.e3. Description: We investigated whether plasma levels of miRNA can differentiate patients with CRC from healthy individuals. We also investigated whether plasma samples from patients with premalignant neoplastic lesions, such as advanced adenomas (AAs), also had a different expression pattern of miRNAs.